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ABSTRACT
Introduction Onchocerciasis is targeted for elimination mainly 
with annual community- directed treatment with ivermectin 
(CDTI). High infection levels have been reported in South- West 
Cameroon, despite ≥15 years of CDTI. The aim of this study 
was to assess factors associated with continued onchocerciasis 
transmission and skin disease.
Methods A large- scale cross- sectional study was conducted 
in 2017 in 20 communities in a loiasis- risk area in South- West 
Cameroon. A mixed- methods approach was used. Associations 
between infection levels, skin disease and adherence to CDTI 
were assessed using mixed regression modelling. Different 
community members’ perception and acceptability of the CDTI 
strategy was explored using semi- structured interviews.
Results Onchocerciasis prevalence was 44.4% among 9456 
participants. 17.5% of adults were systematic non- adherers 
and 5.9% participated in ≥75% of CDTI rounds. Skin disease 
affected 1/10 participants, including children. Increasing 
self- reported adherence to CDTI was associated with lower 
infection levels in participants aged ≥15 years but not in 
children. Adherence to CDTI was positively influenced by 
perceived health benefits, and negatively influenced by fear of 
adverse events linked with economic loss. Concern of lethal 
adverse events was a common reason for systematic non- 
adherence.
Conclusion CDTI alone is unlikely to achieve elimination 
in those high transmission areas where low participation is 
commonly associated with the fear of adverse events, despite 
the current quasi absence of high- risk levels of loiasis. Such 
persisting historical memories and fear of ivermectin might 
impact adherence to CDTI also in areas with historical presence 
but current absence of loiasis. Because such issues are unlikely 
to be tackled by CDTI adaptive measures, alternative strategies 
are needed for onchocerciasis elimination where negative 
perception of ivermectin is an entrenched barrier to community 
participation in programmes.
INTRODUCTION
Onchocerciasis, or river blindness, is a 
neglected tropical disease caused by the 
Key questions
What is already known?
 ► Targeting onchocerciasis elimination rather 
than morbidity control raises new challenges for 
community- directed treatment with ivermectin 
(CDTI), particularly in areas of co- endemicity with 
Loa loa where fear of adverse events negatively im-
pacts on participation and high transmission persists 
despite long- term CDTI.
What are the new findings?
 ► Prevalence was high including among high adherers 
to CDTI (prevalence range 25% to 55% in ≥50 year- 
olds and 9 to 14 year- olds with self- reported high 
adherence, respectively), suggesting persistence of 
high transmission despite 15 rounds of CDTI.
 ► Low adherence to CDTI and interrupted ivermectin 
uptake were mostly due to experienced or observed 
common ivermectin- related adverse events inter-
fering with daily activities as well as their economic 
consequences.
 ► Systematic non- adherence was related to fear of 
death and rumoured severe adverse events, which 
persisted despite the current very low prevalence 
and infection intensity of Loa loa.
 ► Participants who were concerned about serious and 
lethal ivermectin- related adverse events did not di-
rectly relate those issues to loiasis.
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filarial parasite Onchocerca volvulus, transmitted by black-
flies of the genus Simulium.
In 2017, there were an estimated 20.8 million oncho-
cerciasis cases, 99% of which occurred in the poorest 
and most vulnerable populations of sub- Saharan Africa.1 
Onchocerciasis notably causes potentially irreversible 
impaired vision but most commonly presents as skin 
disease, which affects 70% of cases and caused over 90% 
of years lived with disability due to onchocerciasis in 
2017.1–3
The WHO strategy against onchocerciasis consists 
of mass drug administration (MDA) with community- 
directed treatment with ivermectin (CDTI) and has 
shifted its goal from morbidity control to disease elimina-
tion with a target of 12 (31%) endemic countries verified 
for interruption of transmission by 2030.4
By killing the parasite larvae present in the skin, the 
microfilariae (mf), regular ivermectin (IVM) treatment 
both prevents further disease development and trans-
mission to the blackfly vector.5 WHO recommends that 
annual MDA for at least 15 to 17 years of high coverage 
(80%) should reduce transmission and result in decreased 
skin infection incidence in children.2 6
Although 15 to 17 years of CDTI has achieved elimi-
nation in some African settings, high transmission levels 
persist in the face of long- term CDTI campaigns in other 
areas, particularly in communities living and working 
close to blackfly vector breeding sites in forested regions 
where year- round transmission occurs.7–12 An additional 
challenge is the risk of severe adverse events (SAEs) 
following ivermectin treatment in patients harbouring 
heavy Loa loa microfilaraemia, co- endemic with oncho-
cerciasis.13 Reasons for low participation to CDTI are 
numerous and may include absence during drug distri-
bution, negative perception of CDTI, fear of side effects 
and weak community ownership.9 14 15
The aim of this work was to document onchocerciasis 
infection and morbidity levels after 15 years of annual 
CDTI in previously identified persisting onchocerci-
asis hot spots, by assessing their association with adher-
ence to CDTI, and identifying drivers of adherence and 
ivermectin uptake based on the case of these high- risk 
communities in South- West Cameroon.
METHODS
Study area, design and participants
A community- based cross- sectional study was conducted 
between June and October of 2017 in 20 communities 
in the Meme River Basin, South- West region, Cameroon, 
where onchocerciasis transmission was recorded between 
2011 and 2012.7 The assessments presented here were 
conducted during the baseline survey of a controlled 
before- and- after community- based intervention study 
aiming at assessing the impact of WHO- endorsed alter-
native strategies to accelerate the elimination of oncho-
cerciasis, that is, 35- day treatment of onchocerciasis cases 
with 100 mg doxycycline (test and treat with doxycy-
cline), either alone or in combination with ground larvi-
ciding with temephos for vector control. Further details 
are available in the study protocol.16 First, a census of all 
study villagers was undertaken in all communities, and 
those aged ≥5 years and who had lived ≥5 years in the 
community were eligible.
Parasitological and questionnaire data
Enrolled participants were diagnosed for onchocerciasis 
with two skin snips taken from each iliac crest using a 
sterile 2 mm corneo- scleral punch (CT 016 Everhards 
2218–15 C, Meckenheim, Germany). Mf counts were 
expressed as mf per skin snip. L. loa infection was diag-
nosed using a 50 µL thick blood smear prepared with 
blood collected by finger prick. Microfilariae were 
identified under light microscope and the counts were 
expressed as number of microfilariae per millilitre (mf/
mL) of blood.16 Information on socio- demographics, self- 
reported adherence to CDTI and recent medical history 
was collected with individual structured questionnaires. 
Pre- control O. volvulus prevalence and community micro-
filarial load (CMFL) for six of the study communities 
were obtained from previous reports.7 17
Onchodermatitis clinical assessments
Onchodermatitis diagnosis was conducted, using a 
formal clinical classification and coding system, by district 
hospital nursing staff specifically trained by an expert 
dermatologist.16 18
Onchocercal skin disease (OSD) was classified as acute 
papular onchodermatitis (APOD), chronic papular onch-
odermatitis (CPOD), lichenified onchodermatitis, depig-
mentation, atrophy or hanging groin.18 Non- onchocercal 
skin diseases included scabies, dermatophytes and 
pyoderma. Severe itching was defined as either itching 
reported spontaneously with emphasis in response to 
open- ended questions about general health or reported 
when prompted with a follow- up probe asking specifically 
about itching as either troublesome itching disturbing 
sleep or as severe.19
Semi-structured qualitative interviews
To investigate reasons for participation or non- 
participation in annual CDTI, interviews were conducted 
with community members who tested negative for 
Key questions
What do the new findings imply?
 ► CDTI alone, even improved with programme adaptive measures, is 
highly unlikely to eliminate onchocerciasis in such areas, where the 
fear of ivermectin adverse events and death is deeply anchored 
in the population and persists as a reason for systematic non- 
adherence despite the current quasi absence of high- risk levels of 
loiasis in the area.
 ► Other alternative approaches such as vector control with ground 
larviciding and/or treatments avoiding direct microfilaricidal side 
effects, such as doxycycline, might be more acceptable in areas not 
only of current, but also of past co- endemicity with loiasis.
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onchocerciasis and were offered IVM as standard treat-
ment, 24 interviewees accepted and 16 declined IVM. 
Community members were purposefully selected based 
on demographic characteristics including age, sex and 
location.16 Interviews were also conducted with commu-
nity drug distributors (CDD) (n=26) to gain insight into 
their experience of community acceptance of CDTI. 
Interviews were conducted in 9 out of the 10 representa-
tive communities because one community could not be 
accessed (due to a blocked road).
Qualitative data analysis
Interviews were recorded, transcribed verbatim and trans-
lated from Pidgin to English. The transcripts and field 
notes were analysed with NVivo software using a frame-
work approach as described by Ritchie, et al 2013.20 The 
framework was developed both inductively and deduc-
tively. After familiarisation, coding frameworks were 
developed and all data was coded, charted and synthe-
sised by gender and age groups.
Statistical analysis
Census data was collected with ODK (Open Data Kit, 
July 2010, http:// opendatakit. or) and cleaned in Micro-
soft Excel. Parasitological and questionnaire data were 
entered with EpiInfo V.3.5.2 (EpiData Association; 
Odense, Denmark). Further data management and 
analysis were performed in Stata V.15.0 (StataCorp LP; 
College Station, Texas, USA).
Infection status was defined as positive if at least one 
microfilaria was found in either skin snip, or negative 
otherwise. The CMFL, that is, infection intensity at 
community level, was calculated as the geometric mean 
of the community infection intensity among individuals 
aged 20 years and above, including the negatives.21 Self- 
reported adherence to CDTI was expressed as the propor-
tion of rounds taken out of the maximum of rounds the 
person could have taken given their age. Variables were 
categorised as described in online supplemental file 1.
CIs were estimated accounting for the cluster design of 
the study. Pearson’s χ2 test was used to compare propor-
tions. The association between infection levels or symp-
toms of onchocerciasis and adherence to CDTI or other 
variables of interest was assessed using mixed- effects 
logistic (O. volvulus mf prevalence, nodule presence or 
clinical sign prevalence) or negative binomial (mf load) 
regression models with community as a random effect. 
All models were adjusted for factors unevenly distributed 
between participants enrolled or non- enrolled in the 
parasitological study. Other variables were selected based 
on the likelihood ratio test (LRT) at 20% level signifi-
cance and Akaike’s information criterion for correlated 
variables (see online supplemental file 1 for further 
details). Two- way and three- way interactions between age, 
sex and adherence to CDTI, or self- reported adherence 
and time since last treatment were checked and assessed 
using the LRT. CIs for interactions were estimated using 
the Stata ‘lincom’ command. Marginal probabilities of, 
and the effect of adherence levels on, O. volvulus prev-
alence, intensity and nodule prevalence were estimated 
with the respective multivariate models and plotted using 
the Stata command ‘margins’ and ‘marginsplot’.
Ethics statement
All censused individuals were explained the objectives 
and procedures of the intervention study. Informed assent 
was obtained from children and adolescents aged under 
18 years with parental consent, and consent was provided 
by all adult participants (age ≥18 years). All participants 
diagnosed with O. volvulus infection were offered treat-
ment as described in the study protocol paper.16
Role of the funding source
The funder (Department for International Develop-
ment; UK- AID) had no role in study design; in the collec-
tion, analysis and interpretation of data; in the writing 
of the report; or in the decision to submit the paper for 
publication. The corresponding author confirms that he 
has full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
RESULTS
Study population and participation in the baseline survey
Out of a total of 19 915 participants determined by 
community census at baseline, 1935 were aged <5 years, 
8515 were absent, refused to participate or lived <5 years 
in the community, 9 had incomplete demographic data. 
As a result, 9456 (52.6% of eligible) participants were 
included in the parasitological survey. Among those, 238 
and 103 participants had none or incomplete adherence 
to CDTI data, respectively. A study diagram is provided in 
online supplemental file 2 and participant characteristics 
are available in online supplemental file 3.
All models were adjusted for unbalanced characteris-
tics between enrolled and non- enrolled participants, that 
is, age, gender, occupation and education.
Sensitivity analysis of complete cases (presented here) 
versus missing values for incomplete adherence data 
addressed using multiple imputation provided the same 
results, probably due to the low proportion of missing 
values (data not shown).
O. volvulus and L. loa infection levels, and adherence to CDTI
The overall prevalence of O. volvulus was 44.4% (95% CI: 
39.2 to 49.8), ranging between 31.3% (95% CI: 26.5 to 
36.6) and 75.5% (95% CI: 69.7 to 80.7) at community 
level. Three villages were hypoendemic and three were 
still hyperendemic. Study villages endemicity levels are 
displayed in figure 1A. The mean CMFL was 2.06 (range 
across communities: 0.82 to 3.59). A maximum (arith-
metic) mean mf count of 538.5 per skin snip was found 
in a 9- year- old boy. The prevalence of L. loa was 3.7% 
(95% CI: 2.4 to 5.6), range across communities: 1.4% 
to 11.5%). The mean L. loa infection intensity was 49.5 
mf/mL and ranged among positives between 0.5 and 
1860 mf/mL, this maximum being below the 8000 mf/
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mL threshold associated with a high risk for ivermectin- 
related SAEs.
Village level O. volvulus prevalence rates and CMFL, as 
well as L. loa prevalence are available in online supple-
mental file 4.
Most participants (4079/4946, 82.5%) aged ≥20 years 
(ie, who were ≥5 years when CDTI reached 65% coverage) 
declared having taken IVM at least once. Over a quarter 
of participants (17.5%) reported being systematic non- 
adherers (ie, never took IVM), with similar proportions 
among men and women. Only 5.89% (95% CI: 3.57 to 
8.16) of adult participants (age ≥18 years) reported high 
adherence (participation in ≥75% of rounds). Figure 2 
displays age and gender- specific self- reported adher-
ence levels (2A), and proportion of high adherers (2B). 
Adherence increased with increasing age and was lowest 
in the 14 to 29 years, regardless of gender.
Comparison of pre-CDTI and post-CDTI infection levels in a 
subset of communities
Pre- control and current O. volvulus mf prevalence and 
CMFL estimates are displayed in figure 1B. CDTI had a 
strong impact on the CMFL. The impact on prevalence 
was more modest and varied considerably across commu-
nities. Although three of those villages are currently the 
only hypoendemic villages in the area, they still all have 
prevalence rates above 30% (Bombanda 31.3%, Bombele 
32.2% and Small Massaka: 34.3%).
Association between adherence to CDTI, infection levels and 
presence of nodules
Figure 3 displays O. volvulus mf prevalence ((3A), mf load 
(3B) and nodule prevalence (3C)) estimated as a func-
tion of age and self- reported adherence using the mixed- 
multivariate models presented in table 1. Unadjusted 
ORs are presented in online supplemental file 5.
Women had lower infection levels (all three outcomes) 
than men. Recent IVM treatment (≤1 year) was associ-
ated with lower odds of mf or nodule prevalence and 
lower mf loads.
The relationship between self- reported adherence 
and each of the three outcomes varied across age groups 
(effect modification), but not across gender. Self- reported 
adherence to CDTI was associated with lower infection 
levels in participants aged ≥30 years (figure 3D,E), but 
not in children, and its protective effect increased with 
increasing adherence (figure 3A,B).
Our model estimated that, compared with an adher-
ence level of 50% to 75%, adhering to ≥75% of rounds 
resulted in a significant additional mf prevalence 
Figure 1 O. volvulus prevalence in 20 study communities (A) and O. volvulus prevalence and CMFL before and after 15 
rounds of CDTI in six study villages (B). A: Geographical location of, and O. volvulus prevalence in, the 20 study villages. Data 
were obtained from 9456 participants aged 5 years and over in a cross- sectional survey conducted in 2017 in 20 villages 
of South- West Region, Cameroon. This map has been produced in ArcGIS 10.5 specifically for this study. B: O. volvulus 
prevalence and CMFL before and after 15 rounds of CDTI in six of the study villages. Pre- control data were obtained from.7 17 
Data after 15 rounds of CDTI were obtained from a cross- sectional survey conducted in 2017 and including 3062 participants 
aged 5 years and over (prevalence) and 1703 participants aged 20 years and over (CMFL), living in six villages of South- West 
Cameroon. CDTI, community- directed treatment with ivermectin; CMFL, community microfilarial load; O. volvulus, Onchocerca 
volvulus.
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reduction of −9.7% (95% CI: −0.2 to −19.0%) and −15.5% 
(95%CI: −5.4 to −25.7%) in the 30 to 49 years and the 
≥50 years, respectively.
Among high adherers, children had higher infection 
levels than adults aged ≥30 years and this difference was 
Figure 2 Mean proportion of CDTI rounds participated in (A) and proportion of high adherers (B), by age and gender. High 
adherers are defined as participants who took ivermectin in ≥75% of rounds. Denominators for the mean proportion of rounds 
taken are the maximum number of rounds an individual could have participated in given their age. Data were obtained from 
9164 participants aged 5 years and over, with available CDTI adherence data, in a cross- sectional survey conducted in 2017 in 
20 villages of South- West Region, Cameroon. CDTI, community- directed treatment with ivermectin.
Figure 3 O. volvulus skin mf prevalence (A and D), infection intensity (B and E) and nodule prevalence (C and F) by adherence 
level and age. Those predictions were obtained using the multivariate models presented in table 2. Age groups 15 to 19 and 20 
to 39 years had similar infection risk and intensity across adherence levels and were grouped in a larger category (ie, 15 to 29 
years) to increase the precision of estimates. Data were obtained from a cross- sectional survey conducted in 2017, including 
9115 participants with complete data aged 5 years and over living in 20 communities of South- West Cameroon. CDTI, 
community- directed treatment with ivermectin; IVM, ivermectin; mf, microfilariae; O. volvulus, Onchocerca volvulus.
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significant for children and adolescents aged 9 to 14 
years (figure 3A,B).
Nodule prevalence was not associated with adherence 
but increased with age and was significantly higher in 
participants aged above 15 years (figure 3C,F).
Prevalence of clinical signs
OSD affected 10.3% (95% CI: 8.8 to 12.0) of participants, 
most of them (865/972, 89.0%), being diagnosed with 
only one OSD, the others having up to three OSDs.
The prevalence of OSD increased with age, ranging for 
any OSD from 6.57% (95% CI: 5.4 to 8.0) in children 
and adolescents aged below 15 years to 20.6% (95% CI: 
17.0 to 24.7) in adults aged over 50 years. Online supple-
mental file 6 displays the prevalence of OSD among 
participants aged above and below 15 years, that is, 
born before and during the CDTI era. Younger partici-
pants mostly suffered from reactive skin disease whereas 
chronic depigmentation, atrophy, hanging groin (long- 
term development OSD) were more common among 
participants aged over 30 years.
Severe itching affected 5.85% (95% CI: 4.57 to 5.45) 
of participants. Visual impairment/vision problem was 
reported by 2.32% (95% CI: 1.29 to 4.15) of participants.
Non- onchocercal skin disease was rare, with 160 cases 
of infection with dermatophytes (prevalence: 1.69%, 
95% CI: 1.06 to 2.68), 76 cases of pyoderma (prevalence: 
0.08%, 95% CI: 0.06 to 1.07) and 32 cases of scabies 
(prevalence: 0.34%, 95% CI: 0.013 to 0.086).
The prevalence of palpable nodules was 17.1% (95% 
CI: 15.3% to 19.0%) and most participants (94.2%) had 
one to three nodules. The maximum number of palpable 
nodules, 20, was observed in a 65- year- old woman.
Association between onchocercal skin disease, infection 
status and adherence to CDTI
Age- specific OSD prevalence rates were estimated 
using mixed–multivariate regression models. They are 
presented in online supplemental file 7 and illustrated 
in online supplemental file 8. The results of the bivar-
iate analysis (unadjusted ORs) are presented in online 
supplemental file 9. The association between OSD was 
stronger with nodule number than with nodule presence 
(data not shown). Only depigmentation, atrophy and 
severe itching were associated to some extent with infec-
tion levels (either mf presence or load).
In the multivariate analysis, only depigmentation and 
severe itching (borderline non- significance) were associ-
ated with O. volvulus infection while APOD, CPOD and 
depigmentation were positively associated with nodule 
number (online supplemental file 7).
Men and women had similar risks of suffering from 
any OSD. The odds of suffering from depigmentation 
(OR=3.39 (95% CI 2.61 to 4.40) for the 50+ years age 
group compared with participants aged 30 to 49 years) 
or atrophy (OR=2.51 (95% CI 1.56 to 4.05) for the 50+ 
years age group compared with participants aged 30 to 
49 years) increased with age. With regard to adherence 
to CDTI, early onset OSD tended to be positively associ-
ated with increasing adherence but the association was 
significant for APOD only. High adherence appeared to 
be associated with decreased risk of depigmentation and 
atrophy in participants aged 50 years and above, although 
not significantly, probably due to the low proportion of 
high adherers in this setting resulting in small sample size 
for these cross- categories.
Severe itching was more likely to be reported by partic-
ipants aged ≥15 years, women and participants who ever 
took IVM, particularly high adherers. All three forms of 
reactive skin disease were associated with severe itching, 
with an increasing strength of association across APOD 
(OR=3.79, 95% CI (2.58 to 5.56), CPOD (OR=6.63 95% 
CI 4.91 to 8.96) and lichenified onchodermatitis which 
exhibited the strongest association (OR=8.11, 95% CI: 
4.42 to 14.87) (online supplemental file 10).
Perception and acceptability of CDTI
Interviews were conducted with 40 community members 
and 26 CDDs to understand perceptions around IVM 
(online supplemental file 11).
Exposure and awareness
Many community members understood that IVM 
(commonly referred to as ‘Mectizan’) was used to treat 
‘filaria’ (common name for onchocerciasis) which was 
transmitted by ‘Mbitti’ (blackfly), and caused itching, skin 
disease, discolouration of the skin, skin nodules (‘mabo’ 
or ‘horns’), itching eyes and blindness. Most participants 
(of all ages) suggested that ‘filaria’ was very common 
in their communities. All participants reported getting 
bitten by flies (or mosquitoes) frequently and this was 
often associated with being near water or on their farm. 
Other beliefs about transmission included through inter-
course or sharing clothes, with some rare reports that it 
was hereditary. Measures taken to prevent bites included; 
covering skin as much as possible, especially feet; use 
of medicated soap, improved hygiene and not sharing 
clothes.
‘It is because I always mask myself from my head, all my skin, 
except my neck that I do not cover’ (Community member, 
man aged 15 to 20 years).
Acceptance of CDTI
There were many structural, social, economic and health 
factors identified by the communities which contrib-
uted to adherence or non- adherence to IVM which are 
outlined in table 2.
The most prominent barriers and facilitators for CDTI 
were centred around acceptability, including affordability 
of taking IVM. CDDs reported that the acceptability of 
‘Mectizan’ varied in households with some accepting and 
others not. The main driver identified by community 
members for taking ‘Mectizan’ was its perceived health 
benefits of reducing symptoms and treating ‘hidden 
disease’. Older adults (aged >40 years) were the most 
likely to recognise health benefits from taking ‘Mectizan’, 
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Table 2 Summary table of barriers and motivators for uptake of CDTI
Thematic areas Barriers to CDTI uptake
Motivators/facilitators for CDTI 
uptake
Awareness Lack of understanding about blackfly 
vector specific transmission
Understanding of transmission, 
prevention and treatment of 
onchocerciasis (education in school)
Limited understanding of prevention and 
treatment
Observed reduction in community 
morbidity
'The benefit of this Mectizan programme 
is that it has helped the community from 
blindness. …many people would have 
been blind and parents in those days and 
even youths had leopard legs…’ (CDD, 
man, aged 31–40 years)
Availability Distribution timing of CDTI (community 
members being absent from community as 
on the farm)
Regular distribution with supplies 
available from other sources if missed 
distribution or symptomatic.
‘They distribute it from house to house. 
But if you have itches you can go to the 
pharmacy and pay a 100 FRS to get 
Mectizan’ (Community member, man, 
aged 15–20 years)
Demotivation from CDDs due to lack of 
intrinsic and/or extrinsic motivation
Financial and/or non- financial 
motivational structures in place
Accessibility Seasonality of CDTI (CDDs being unable to 
access rural communities because of lack of 
resources such as umbrellas and boots)
‘What I find very difficult in the task is, 
transportation is difficult especially during 
the rainy season when we must use materials 
like)umbrellas, shoes etc.’ (CDD, man, aged 
41–50 years)
Medication is free‘
The benefit to the community is that we 
benefit the Mectizan for free. So, we do 
not pay transport and if we were to be 
paying transport to go and get it, am 
not sure that even twenty people would 
go and get the Mectizan’ (Community 
member, woman, aged 41–50 years)
House to House distribution
Acceptability Side effects(experienced, observed 
in others or rumoured) (see online 
supplemental file 12 for more details)
Health benefits (experienced or 
observed in others / preventative and 
symptom control)
‘Sometimes my eyes cannot really 
open but when I take the mectizan, my 
eyes will open. So, it depends as every 
person has its own benefits just as I just 
said mine. I have benefits in mectizan 
and that is why I now trust mectizan’ 
(Community member, woman, aged 41 
to 50 years)
Fears of ‘hidden’ disease or provoking 
disease
'When Mectizan just came I heard many 
people say that “you people should not 
take Mectizan oh… Mectizan will wake up 
all diseases in your body. Sometimes it 
can generate a sick in you when you don’t 
have money and that is how you will die' 
(Community member, woman aged 41–
50 years).
Encouragement from parents 
(especially mothers) or other members of 
the community
Continued
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which mostly included improvement in eyesight and 
reduction in blindness.
The main barrier to accepting ‘Mectizan’ for community 
members was fear of adverse events (online supplemental 
file 12). Even if community members perceived associ-
ated health benefits, for some this was over- ridden by 
fear of adverse events, such as swelling and increased 
itching, or fear of ‘provoking’ other sickness. Some had 
Thematic areas Barriers to CDTI uptake
Motivators/facilitators for CDTI 
uptake
Association with witchcraft Belief ivermectin will treat multiple 
diseases'
The benefit is that we should drink it and 
it should stop any illness that is filarial in 
anybody’s body.’ (Community member, 
woman, aged 41 to 50 years)
Perceived exclusion criteria of ineligibility 
to take Mectizan due to other health 
conditions (such as pregnancy, epilepsy, 
hernias, alcohol consumption)
‘We were told not to give epileptic patients 
mectizan, and equally some men who 
complained that they have Hernia and that 
they cannot take mectizan’ (CDD, woman, 
aged 31–40 years)
Medication to treat side effects is free
Discouragement from others (eg, family or 
palm wine makers)
Being able to receive free treatment 
for side effects from CDDs or be 
referred to a health facility
‘Most of them go to the health centre 
and they are given drugs to cold down 
all the pains.’ (Community member, 
man, aged 41–50 years) (see online 
supplemental file 12) for more details)
Fear of death
‘Some people take the drugs while others 
do not mainly because of the side effects 
like swollen bodies, itches and rashes. 
Some people in the community when you 
have witchcraft and you take mectizan, you 
will die. So, some people too refuse taking 
it because one may have witchcraft and 
is not aware of it. So, they prefer not to 
take it at all.’ (Female community member 
15–20 years)
‘Some people decide that they will never 
take Mectizan again· For example, an old 
man said that he took Mectizan and it almost 
killed him and concluded that he will never 
take it again in his lifetime’ (Community 
member, man, aged 31–40 years)
Costs of treating side effects, especially 
hernias
Economic costs of missing work or 
school because of side effects
‘I said no· because I am in a rural area and 
if I take all at once and it gives me a severe 
side effect that will disturb me from going 
to my farm, then I will have to absent from 
my farm.’ (Community member, man, aged 
41–50 years)
CDD, community drug distributor; CDTI, community- directed treatment with ivermectin.
Table 2 Continued
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taken ‘Mectizan’ in the past and experienced a negative 
reaction and therefore would not accept it again, while 
others had heard of negative effects in the community 
and therefore would not take it at all. Fear around side 
effects of ‘Mectizan’ and associations with death were 
highlighted both by community members and CDDs. 
Fears of death were reported as ‘Mectizan’ was thought 
to make the conditions worse or provoke other diseases 
or activate malaria, typhoid, rheumatism and especially 
hernias. which were perceived to worsen when taking 
‘Mectizan’. Several community members reported that 
they never participated in CDTI due to rumoured reports 
of deaths or observed side effects.
‘I have not been taking because I am afraid because some 
people say when they take, they get swollen and others die. So 
that has made me never to take mectizan, and I have never taken 
mectizan.’ (Male community member 31 to 40 years).
Fear of economic consequence of adverse events, 
such as needing treatment or missing work was given as 
a justification for not accepting ‘Mectizan’, particularly 
for those who worked on farms, especially around the 
cocoa season. An older man reported that ‘It disturbs them 
from going to the farm and carry out other personal, social and 
commercial activities’. (Community member, man, aged 
60+ years).
Not having the money to pay for healthcare or treat-
ment created fears that they could die from side effects if 
they took ‘Mectizan’.
Other social, economic and health consequences of 
adverse events was also noted by CDDs and community 
members (online supplemental file 12), such as fear of 
fertility problems or causing miscarriage, fear of hernias 
needing surgery as well as becoming a burden to the 
family by being unable to attend work or school, or being 
unable to socially interact due to adverse events, particu-
larly itching or reduced mobility.
It makes me to feel uncomfortable when I want to sit with my 
friends… Because I cannot go and sit among my friends and be 
scratching my skin (Community member, man, aged 15 to 
20).
Those that did accept ‘Mectizan’ may try to miti-
gate potential adverse events through changing how it 
was consumed, for example, it was reported that some 
community members would grind ‘Mectizan’ and add it 
to ‘rubbing oil’ therefore instead of ingesting the medica-
tion, it was applied directly to their skin. This was seen by 
a few to reduce the severity of adverse events.
DISCUSSION
After over 15 years of CDTI with ≥65% programmatic 
therapeutic coverage, we report O. volvulus prevalence as 
high as 44.4% in a sample of over 9000 individuals aged 
5 years and above and living in 20 villages of South West 
Region, Cameroon.7 Only three villages were found to be 
hypoendemic, and prevalence was above 30% in all 20 
communities.
CDTI has been an effective control measure
The low CMFL in all communities and its dramatic drop 
even in communities with very high pre- control indica-
tors, show a strong impact of CDTI on infection inten-
sity, similarly to other settings, and suggests that CDTI 
has been an effective control measure.7 10 17 Additionally, 
there was an overall low prevalence of late onset OSD 
mostly affecting older participants when compared with 
various pre- control studies.22–26 The reduction of severe 
morbidity was also perceived by community members, 
especially the older participants and CDDs who reported 
that they observed a reduction of blindness and severe 
skin disease since CDTI began.
Using the same OSD classification, pre- control data 
and current OSD estimates in the Kumba district, the 
prevalence of nodules, depigmentation, early onset skin 
disease and severe itching were found to be 46%, 29.8%, 
21.7, % and 21.4% in the late 90s and dropped to 17%, 
3.4%, 5.4% and 5.8%, respectively, in 2017.18 22 Reduc-
tion in OSD and severe itching prevalence following 
several years of CDTI has also been reported in African 
Programme for Onchocerciasis Control (APOC) sentinel 
sites, with declining rates varying with therapeutic 
coverage.3 24 27 IVM treatment within a year before the 
study was associated with lower infection levels as well 
as with lower odds of having nodules, the latter possibly 
reflecting the partial macrofilaricidal activity of repeated 
doses.28
Adherence was associated with lower infection levels in 
participants aged ≥15 years only, and increased participa-
tion resulted in increased protective effect of treatment, 
reflecting the impact of long- term ivermectin uptake.2 29
Effectiveness is suboptimal and CDTI alone is unlikely to 
achieve elimination in this setting
In addition to high onchocerciasis prevalence, over one- 
third (35.8%) of adults and 15.9% of children born in 
the CDTI era had nodules and/or suffered from OSD 
and/or severe itching, indicating a suboptimal impact of 
treatment and persisting transmission.10 The prevalence 
of early onset skin disease (acute or chronic papular 
onchodermatitis) was similar in participants aged below 
or above 15 years.
Challenge 1: transmission and exposure
Children (age <15 years, that is, born in the ‘CDTI era’) 
had overall similar mf prevalence and mf loads as partic-
ipants aged ≥15 years. Low or absent infection levels 
in young children would be supportive of a decrease 
or block in transmission following implementation of 
CDTI, but this pattern was not supported by our find-
ings. The only group with significantly lower infection 
levels than adults were children aged 5 to 8 years who 
never took ivermectin. While the absence of association 
between treatment and infection levels in children could 
be due to reporting bias, we found that systematic non- 
adherence was highest in this age group (52.6%), prob-
ably because children aged 5 to 6 years might not have yet 
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participated into CDTI due to their age versus distribu-
tion timing. This high reported non- participation would 
be in favour of accurate reports, even more so since chil-
dren were assisted by their parents in answering question-
naires. Additionally, children aged 5 to 8 years identified 
as high adherers were more likely to exhibit OSD symp-
toms than others, suggesting that the presence of symp-
toms might have led parents to give them treatment. This 
result would be in line with the assessment of association 
(which go both ways) and not causality.
As a comparison, reported systematic non- adherence 
by older children aged 9 to 14 years was much lower 
(21.6%) and might more likely result from response 
bias due to social desirability. This absence of associa-
tion between ivermectin uptake and infection levels in 
participants aged less than 15 years has previously been 
reported in the area and has been attributed to response 
bias as children tend to give answers that they think are 
expected from them.30 31 Yet, this bias might have been 
mitigated by parents assisting children up to 15 years in 
answering questions. Another reason, suggesting high 
transmission in the area, could be behaviour favouring 
exposure of children and adolescents, as previously 
reported in Cameroon.7 32
In participants aged over 15 years, self- reported adher-
ence to CDTI was associated with decreased incidence of 
skin infection. Yet, our fully adjusted models estimated 
that the lowest prevalence rates remained at over 25%, 
among older adults with high adherence. High preva-
lence rates in high adherers might relate to the local 
high transmission potential. Although this will need to 
be corroborated by entomological studies, blackfly biting 
rates appeared high as community members reported 
frequent bites on their farms or while at the river for 
social or domestic activities. The Meme River basin was 
previously found to have the highest entomological 
indices in the area, with over 1000 infective larvae/
man/month in some communities.7 Participants lived 
and worked extremely close to the rivers and attempts 
to prevent exposure through clothing was often insuffi-
cient in preventing bites. Our results indicate that the 
CDTI strategy had suboptimal impact in suppressing 
skin infections to prevent transmission in both chil-
dren and adults although with contrasting self- reported 
adherence patterns. A second factor contributing to 
persistent high prevalence could be the selection of 
O. volvulus more refractory to ivermectin occurring in 
areas with higher drug pressure due to long- term CDTI, 
which has previously been documented in Cameroon 
and Ghana.33–35
Model- based treatment duration requirements for 
breaking transmission in hyperendemic settings with 
annual CDTI at coverage above 65% range between 10 
years (for a 62% pre- control prevalence) and >25 years.6 
The comparison of pre- control and current estimates 
for one- third of our study villages indicate that they are 
far below the more optimistic targets, with only one 
being within model- based prediction ranges and current 
estimates being more in line with elimination not occur-
ring even after 25 years of CDTI.6
Challenge 2: adherence
Adherence was particularly low in our study setting. Only 
half (52.8%) of adults participated in CDTI the year 
preceding the study, and as few as 5.7% reported having 
participated in at least 12 of 16 (ie, ≥75%) CDTI rounds 
(high adherers). We also found that adherence was lowest 
in adolescents and young adults (aged 15 to 29), which is 
in line with findings from West Cameroon.9 In the present 
study, low participation of the youth was mostly due to 
a lack of perceived need based on an absence or lack 
of awareness regarding associated morbidities such as 
chronic skin and ocular disease. While perceived health 
benefits or seriousness of disease have been reported 
as an important driver of adherence in Cameroon and 
Nigeria, in some settings, consequences of adverse 
events outweighed perceived health benefits.14 36 Lower 
perceived benefits in the young might lead to decreasing 
adherence in further rounds, both by this generation and 
their children in settings where morbidity declined due 
to successful control of onchocerciasis.9 37 38
Systematic non- adherence, 17.6% among adults, 
was extremely high, even compared with other areas 
of Cameroon, and is of major concern as model- based 
predictions suggest that elimination cannot be achieved 
in originally hyperendemic communities with 5% of 
systematic non- adherence.9 14 29 Reasons for suboptimal 
uptake of CDTI are variable and include systemic as 
well as individual factors.8 9 14 15 39 Programmatic factors 
associated with low adherence in this setting included 
limited access and availability of CDTI due to the timing 
and seasonality of distribution, which is in line with other 
findings in West Cameroon.9 However, the recommended 
strategy of biannual or pluriannual CDTI in areas of low 
adherence would unlikely overcome adherence issues in 
this setting, as acceptability of IVM treatment appeared 
to be the main driver of (non- )adherence.
An important finding is that the nature of adverse 
events reported as reasons for interrupted participation 
(low adherence) and systematic non- adherence were 
different. Low adherence appeared to relate to the fear 
of common and non- serious ivermectin- related AEs 
interfering with daily activities, a cause of low adherence 
that has been reported by many studies, including in 
Cameroon.9 37 We also found that an important deter-
rent to participation was the fear around the economic 
consequences of AEs, including treatment affordability, 
work incapacity and subsequent loss of income and diffi-
culties in accessing health facilities. With recognition that 
onchocerciasis affects the world’s poorest and marginal-
ised people the economic consequences of adverse events 
from IVM may continue to perpetuate poverty, and there-
fore should not be overlooked.40
Systematic non- adherence appeared to be associated 
to the fear of rumoured reports of deaths or observed 
adverse events (ie, not personally experienced), which 
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are likely linked to SAEs that occurred in regions of 
L. loa co- endemicity, which is the case in South- West 
Cameroon.13 41 42 The fear of adverse events is a common 
reason for low adherence to CDTI in areas of loiasis 
co- endemicity and recommendations to tackle this issue 
include; lengthy communication strategies with commu-
nities, rapid epidemiological assessments, materials devel-
opment, training, advocacy, community sensitisation and 
mobilisation, case management and counselling, supervi-
sion, monitoring and evaluation.41 Additionally, in areas 
where the population associates ivermectin- related SAEs 
and deaths with loiasis, the use of the LoaScope- based 
Test and Not Treat strategy to identify and exclude from 
treatment L. loa cases at risk for SAEs might help increase 
adherence.43
Yet, our findings suggest that none of those solu-
tions might help overcome low adherence to CDTI and 
achieve elimination in this area. First, the Test and Not 
Treat strategy might not help reassuring the population 
as it would not lead to the exclusion of any individuals 
in these communities due to the current low intensity of 
loiasis in this region.44 45 Importantly, while participants 
reported fear of SAEs (and death) that are known to be 
related to ivermectin treatment in case of heavy infec-
tion with loiasis, they did not directly associate them with 
loiasis. Rather, they associated those SAEs with witch-
craft, or as revealing severe diseases previously ‘hidden’ 
in the body such as malaria, typhoid or hernias. There-
fore, it appears unlikely that CDTI adaptive measures 
would overcome deeply anchored fears and beliefs partly 
relating to historical memory of SAEs in this area with a 
history of low- to- moderate endemicity.45 This persistence 
of the fear of SAEs and death in areas where the actual 
risk of ivermectin SAEs is virtually non- existent, could be 
a major obstacle to onchocerciasis elimination. Indeed, it 
might also affect populations who are not directly at risk 
for SAEs but live in settings where historical memories of 
SAEs and deaths have been perpetuated including when 
originating from other communities. This issue should 
not be overlooked as it might affect up to 79 million 
persons living in the areas of currently low- to- moderate 
loiasis risk within the 11 APOC countries.45
Limitations
Our study has several limitations. First, the low enrol-
ment rate, a common issue with skin snipping, likely 
resulted in an underestimation of our infection and 
morbidity estimates as low or non- adherers, who are also 
more likely to be infected and suffer from OSD, might 
be less inclined to participate in studies.46 Yet estimates 
produced by regression models were adjusted for imbal-
anced characteristics due to non- participation and there-
fore unbiassed. Second, the cross- sectional design of this 
work cannot infer causality and longitudinal studies are 
needed to adequately quantify the impact of adherence 
to CDTI on infection levels and morbidity. Third, adher-
ence to CDTI was assessed through self- reporting, which 
is known to be subject to recall bias. Still, some studies 
have established that most CDTI participants (>60%) 
are able to correctly recall their number of treatment 
and comparisons have indicated that reported coverage 
is overall similar to surveyed coverage.47 48 Although 
response bias from children is likely, the clear inverse 
relationship between self- reported adherence expressed 
in broad percentage categories and infection levels in 
adults suggests that the recollection of participation in 
CDTI over 15 annual rounds by adults was generally an 
accurate reflection of adherence. Additionally, systematic 
non- adherence is likely to be adequately reflected as it is 
not subject to memory recollection.9
CONCLUSION
CDTI is facing major issues to achieve elimination of 
onchocerciasis in this area of current very low, but past 
low- to- moderate loiasis co- endemicity. In those originally 
hyperendemic communities located close to breeding 
sites, onchocerciasis transmission is still high despite 15 
rounds of CDTI, with high prevalence persisting among 
high adherers. Of particular concern is the extremely 
high systematic non- adherence, with over one in six 
adults reporting having never taken ivermectin. Despite 
the current very low prevalence of loiasis in the area, 
an important reason for systematic non- adherence was 
the fear of ivermectin- related SAEs or death which were 
historically reported in the region.42 Yet those SAEs were 
not perceived as associated with loiasis by community 
members. It therefore appears unlikely that CDTI alone 
will achieve elimination in areas where both parasites have 
long co- existed and deeply rooted negative perception of 
ivermectin persisted despite the quasi disappearance of 
high- risk levels of loiasis, even if access, community sensi-
tisation and management of adverse events were to be 
improved. Other alternative approaches such as vector 
control with ground larviciding or treatment with doxy-
cycline, a macrofilaricidal antibiotic that avoids adverse 
events due to the absence of direct microfilaricidal 
activity, might be more acceptable to these communi-
ties.49 Additionally, CDTI effectiveness might potentially 
be further impacted by the selection of O. volvulus that 
are less sensitive to IVM following long- term treatments. 
Alternative strategies are needed to tackle onchocerciasis 
in regions of persisting high prevalence and low CDTI 
adherence, particularly in areas of current but also past 
co- endemicity with loiasis.50–54
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